Business

2 Stocks Reach Important Points: Reed's, Inc. (REED), Moleculin Biotech, Inc. (MBRX)


The consensus rating is 0, indicating analysts in general look favorably on the company’s future prospects.


Moleculin Biotech, Inc. (NASDAQ:MBRX) closed down 0 points or 0.3% at $0.91 with 0.3 mln shares exchanging hands.


Sell-side analyst recommendations point to a short term price target of $3 on the company shares.


The consensus rating is 2, indicating analysts in general look favorably on the company’s future prospects.


The analyst recommendations from a month ago are 2 Buy, 0 Overweight, 0 Sell, 0 Hold and 0 Underweight.


Over the past five trading sessions shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) are -8.27%; -26.98% for the month; -35.73% for the last quarter; -34.34% for the past six-months; and -51.44% for the last 12 months.The current price is staying below the SMA lines which signify weakens and is generally unhealthy/negative and may provide the momentum for driving the share price lower.






Powered by Blogger.